Intramuscular injection of AAV8 in mice and macaques is associated with substantial hepatic targeting and transgene expression

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Greig, Jenny A ^a   Peng, Hui ^a   Ohlstein, Jason ^a   Medina Jaszek, C Angelica ^a   Ahonkhai, Omua ^a   Mentzinger, Anne ^a   Grant, Rebecca L ^a   Roy, Soumitra ^a   Chen, Shu Jen ^a   Bell, Peter ^a   Tretiakova, Anna P ^a   Wilson, James M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALIPOGENE TIPARVOVEC; CD4 IMMUNOGLOBULIN; FIREFLY LUCIFERASE; MICRORNA;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; GASTROCNEMIUS MUSCLE; GENE CASSETTE; GENE EXPRESSION; GENE TARGETING; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; INTRAMUSCULAR DRUG ADMINISTRATION; LIVER; MALE; MOUSE; NONHUMAN; PROTEIN LOCALIZATION; PROTEIN SECRETION; REAL TIME POLYMERASE CHAIN REACTION; RHESUS MONKEY; RNA ISOLATION; TISSUE SPECIFICITY; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS STRAIN; ADMINISTRATION AND DOSAGE; ANIMAL; ANTIBODY SPECIFICITY; DEPENDOPARVOVIRUS; GENE TRANSFER; GENE VECTOR; GENETICS; METABOLISM;

MACACA; MUS;

ANIMALS; DEPENDOVIRUS; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; INJECTIONS, INTRAMUSCULAR; LIVER; MACACA MULATTA; MALE; MICE; MICRORNAS; ORGAN SPECIFICITY; TRANSGENES;

EID: 84911476722     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0112268     Document Type: Article

References (53)

1. Herzog RW, Yang EY, Couto LB, Hagstrom JN, Elwell D, et al. (1999) Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med 5: 56-63.
2. Manno CS, Chew AJ, Hutchison S, Larson PJ, Herzog RW, et al. (2003) AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 101: 2963-2972.
3. Kay MA, Manno CS, Ragni MV, Larson PJ, Couto LB, et al. (2000) Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 24: 257-261.
4. Arruda VR, Schuettrumpf J, Herzog RW, Nichols TC, Robinson N, et al. (2004) Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1. Blood 103: 85-92.
5. Herzog RW, Fields PA, Arruda VR, Brubaker JO, Armstrong E, et al. (2002) Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy. Hum Gene Ther 13: 1281-1291.
6. Flotte TR, Trapnell BC, Humphries M, Carey B, Calcedo R, et al. (2011) Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing alpha1-antitrypsin: interim results. Hum Gene Ther 22: 1239-1247.
7. Brantly ML, Chulay JD, Wang L, Mueller C, Humphries M, et al. (2009) Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc Natl Acad Sci U S A 106: 16363-16368.
8. Rivera VM, Gao GP, Grant RL, Schnell MA, Zoltick PW, et al. (2005) Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. Blood 105: 1424-1430.
9. Johnson PR, Schnepp BC, Zhang J, Connell MJ, Greene SM, et al. (2009) Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med 15: 901-906.
10. Balazs AB, Chen J, Hong CM, Rao DS, Yang L, et al. (2012) Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 481: 81-84.
11. EMA (2012) Assessment Report: Glybera. European Medicines Agency, London.
12. Song S, Scott-Jorgensen M, Wang J, Poirier A, Crawford J, et al. (2002) Intramuscular administration of recombinant adeno-associated virus 2 alpha-1 antitrypsin (rAAV-SERPINA1) vectors in a nonhuman primate model: safety and immunologic aspects. Mol Ther 6: 329-335.
13. Herzog RW, Hagstrom JN, Kung SH, Tai SJ, Wilson JM, et al. (1997) Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Natl Acad Sci U S A 94: 5804-5809.
14. Kessler PD, Podsakoff GM, Chen X, McQuiston SA, Colosi PC, et al. (1996) Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci U S A 93: 14082-14087.
15. Toromanoff A, Cherel Y, Guilbaud M, Penaud-Budloo M, Snyder RO, et al. (2008) Safety and efficacy of regional intravenous (r.i.) versus intramuscular (i.m.) delivery of rAAV1 and rAAV8 to nonhuman primate skeletal muscle. Mol Ther 16: 1291-1299.
16. Mount JD, Herzog RW, Tillson DM, Goodman SA, Robinson N, et al. (2002) Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood 99: 2670-2676.
17. Mingozzi F, Liu YL, Dobrzynski E, Kaufhold A, Liu JH, et al. (2003) Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J Clin Invest 111: 1347-1356.
18. Dobrzynski E, Mingozzi F, Liu YL, Bendo E, Cao O, et al. (2004) Induction of antigen-specific CD4+ T-cell anergy and deletion by in vivo viral gene transfer. Blood 104: 969-977.
19. Dobrzynski E, Fitzgerald JC, Cao O, Mingozzi F, Wang L, et al. (2006) Prevention of cytotoxic T lymphocyte responses to factor IX-expressing hepatocytes by gene transfer-induced regulatory T cells. Proc Natl Acad Sci U S A 103: 4592-4597.
20. Cao O, Dobrzynski E, Wang L, Nayak S, Mingle B, et al. (2007) Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer. Blood 110: 1132-1140.
21. Hoffman BE, Dobrzynski E, Wang L, Hirao L, Mingozzi F, et al. (2007) Muscle as a target for supplementary factor IX gene transfer. Hum Gene Ther 18: 603-613.
22. Breous E, Somanathan S, Vandenberghe LH, Wilson JM (2009) Hepatic regulatory T cells and Kupffer cells are crucial mediators of systemic T cell tolerance to antigens targeting murine liver. Hepatology 50: 612-621.
23. Martino AT, Nayak S, Hoffman BE, Cooper M, Liao G, et al. (2009) Tolerance induction to cytoplasmic beta-galactosidase by hepatic AAV gene transfer: implications for antigen presentation and immunotoxicity. PLoS One 4: e6376.
24. Breous E, Somanathan S, Bell P, Wilson JM (2011) Inflammation promotes the loss of adeno-associated virus-mediated transgene expression in mouse liver. Gastroenterology 141: 348-357, 357 e341-343.
25. Wang B, Li J, Fu FH, Chen C, Zhu X, et al. (2008) Construction and analysis of compact muscle-specific promoters for AAV vectors. Gene Ther 15: 1489-1499.
26. Wang L, Calcedo R, Nichols TC, Bellinger DA, Dillow A, et al. (2005) Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy. Blood 105: 3079-3086.
27. Wang L, Nichols TC, Read MS, Bellinger DA, Verma IM (2000) Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver. Mol Ther 1: 154-158.
28. Lagos-Quintana M, Rauhut R, Meyer J, Borkhardt A, Tuschl T (2003) New microRNAs from mouse and human. RNA 9: 175-179.
29. Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, et al. (2007) A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 129: 1401-1414.
30. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, et al. (2005) A microRNA polycistron as a potential human oncogene. Nature 435: 828-833.
31. Meister G (2007) miRNAs get an early start on translational silencing. Cell 131: 25-28.
32. Qiao C, Yuan Z, Li J, He B, Zheng H, et al. (2011) Liver-specific microRNA-122 target sequences incorporated in AAV vectors efficiently inhibits transgene expression in the liver. Gene Ther 18: 403-410.
33. Geisler A, Jungmann A, Kurreck J, Poller W, Katus HA, et al. (2011) microRNA122-regulated transgene expression increases specificity of cardiac gene transfer upon intravenous delivery of AAV9 vectors. Gene Ther 18: 199-209.
34. Kim HK, Lee YS, Sivaprasad U, Malhotra A, Dutta A (2006) Muscle-specific microRNA miR-206 promotes muscle differentiation. J Cell Biol 174: 677-687.
35. Geisler A, Schon C, Grossl T, Pinkert S, Stein EA, et al. (2013) Application of mutated miR-206 target sites enables skeletal muscle-specific silencing of transgene expression of cardiotropic AAV9 vectors. Mol Ther 21: 924-933.
36. Limberis MP, Adam VS, Wong G, Gren J, Kobasa D, et al. (2013) Intranasal antibody gene transfer in mice and ferrets elicits broad protection against pandemic influenza. Sci Transl Med 5: 187ra172.
37. Balazs AB, Bloom JD, Hong CM, Rao DS, Baltimore D (2013) Broad protection against influenza infection by vectored immunoprophylaxis in mice. Nat Biotechnol 31: 647-652.
38. Glamann J, Burton DR, Parren PW, Ditzel HJ, Kent KA, et al. (1998) Simian immunodeficiency virus (SIV) envelope-specific Fabs with high-level homologous neutralizing activity: recovery from a long-term-nonprogressor SIV-infected macaque. J Virol 72: 585-592.
39. Glamann J, Hirsch VM (2000) Characterization of a macaque recombinant monoclonal antibody that binds to a CD4-induced epitope and neutralizes simian immunodeficiency virus. J Virol 74: 7158-7163.
40. Robinson JE, Franco K, Elliott DH, Maher MJ, Reyna A, et al. (2010) Quaternary epitope specificities of anti-HIV-1 neutralizing antibodies generated in rhesus macaques infected by the simian/human immunodeficiency virus SHIVSF162P4. J Virol 84: 3443-3453.
41. Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, et al. (2010) Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329: 811-817.
42. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, et al. (2010) Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329: 856-861.
43. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, et al. (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326: 285-289.
44. Karali M, Manfredi A, Puppo A, Marrocco E, Gargiulo A, et al. (2011) MicroRNA-restricted transgene expression in the retina. PLoS One 6: e22166.
45. Brown BD, Venneri MA, Zingale A, Sergi Sergi L, Naldini L (2006) Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer. Nat Med 12: 585-591.
46. Gentner B, Schira G, Giustacchini A, Amendola M, Brown BD, et al. (2009) Stable knockdown of microRNA in vivo by lentiviral vectors. Nat Methods 6: 63-66.
47. Wang L, Louboutin JP, Bell P, Greig JA, Li Y, et al. (2011) Muscle-directed gene therapy for hemophilia B with more efficient and less immunogenic AAV vectors. J Thromb Haemost 9: 2009-2019.
48. Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, et al. (2011) Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 365: 2357-2365.
49. Wright JF, Hauck B, Zhou S-Z, Zelenaia O, Sumaroka M, et al. (2013) Concentration of AAV8 and 9 Vector to Titers Ranging from 1-6x1014 vg/mL: Feasibility Assessment for Volume-Limited Dosing. Molecular Therapy 21: S210-211.
50. Gao G, Lu Y, Calcedo R, Grant RL, Bell P, et al. (2006) Biology of AAV serotype vectors in liver-directed gene transfer to nonhuman primates. Mol Ther 13: 77-87.
51. Calcedo R, Vandenberghe LH, Gao G, Lin J, Wilson JM (2009) Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis 199: 381-390.
52. Bell P, Limberis M, Gao G, Wu D, Bove MS, et al. (2005) An optimized protocol for detection of E. coli beta-galactosidase in lung tissue following gene transfer. Histochem Cell Biol 124: 77-85.
53. Bell P, Moscioni AD, McCarter RJ, Wu D, Gao G, et al. (2006) Analysis of tumors arising in male B6C3F1 mice with and without AAV vector delivery to liver. Mol Ther 14: 34-44.